HCA Healthcare (HCA) Stock Forecast & Price Target

HCA Healthcare is viewed favorably because its unmatched scale, leading market positions in 43 domestic markets, and deep presence in fast-growing urban areas support durable patient demand and pricing power. Its operating outlook is strengthened by a resilient business mix, expanding outpatient verticals, and a management team that expects cost reductions and sequential improvement in adjusted EBITDA, while still targeting long-term EBITDA growth of +4-6% yty. Financially, the company’s $5.0–$5.5 billion 2026 CapEx plan, ample balance-sheet capacity, and disciplined resiliency program across revenue integrity, asset optimization, and cost control provide room for reinvestment, share repurchases, and M&A.

HCA Healthcare is facing a deteriorating near-term earnings setup as hospital survey data showed August revenue growth slowing to +0.8% year over year, with weighted average July/August growth of +1.9% versus 2Q26’s +2.7%, reflecting weaker lower-acuity volumes, a worse payor mix, and softer surgical growth. Management’s FY26 adj EBITDA is being pressured by an estimated ~$1.3 billion HIX headwind, while reimbursement lag, rising staffing costs, and continued contract labor reliance threaten margins despite some offset from cost reductions. Its scale and urban market leadership help, but the stock looks vulnerable because competitive intensity, regulatory and government-payor exposure, and possible multiple compression could weigh on results if volume or mix trends fail to improve.